Jules Bordet Institute
π§πͺBelgium
- Country
- π§πͺBelgium
- Ownership
- Private
- Established
- 1939-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.bordet.be
Lapatinib and Temozolomide for the Treatment of Progressive Brain Disease in HER-2 Positive Breast Cancer
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-02-14
- Last Posted Date
- 2012-09-19
- Lead Sponsor
- Jules Bordet Institute
- Target Recruit Count
- 18
- Registration Number
- NCT00614978
- Locations
- π§πͺ
Jules Bordet Institute, Brussels, Belgium
Magnetic Resonance Imaging for the Early Detection of CNS Metastases in Women With Stage IV Breast Cancer
Not Applicable
- Conditions
- First Posted Date
- 2006-11-10
- Last Posted Date
- 2013-08-12
- Lead Sponsor
- Jules Bordet Institute
- Target Recruit Count
- 96
- Registration Number
- NCT00398437
- Locations
- π§πͺ
Institut Jules Bordet, Brussels, Belgium
π§πͺCentre Hospitalier Etterbeek Ixelles, Brussels, Belgium
π§πͺCentre Hospitalier Universitaire Brugmann, Brussels, Belgium
Adjuvant Capecitabine in Elderly Patients With Breast Cancer: a Phase II Study
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-12-09
- Last Posted Date
- 2011-02-24
- Lead Sponsor
- Jules Bordet Institute
- Target Recruit Count
- 43
- Registration Number
- NCT00263705
- Locations
- π§πͺ
Jules Bordet Institute, Brussels, Belgium
Comparing Hepatic Intra-arterial Injection of Yttrium-90 Microspheres Versus Fluorouracil (5FU) in Colorectal Cancer Metastatic to the Liver Only
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2011-02-24
- Lead Sponsor
- Jules Bordet Institute
- Registration Number
- NCT00199173
- Locations
- π§πͺ
Jules Bordet Institute, Brussels, Belgium
PS-341 in Combination With Herceptin in Advanced Breast Cancer That Overexpresses HER-2
Phase 1
Completed
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2011-02-24
- Lead Sponsor
- Jules Bordet Institute
- Target Recruit Count
- 19
- Registration Number
- NCT00199212
- Locations
- π§πͺ
Jules Bordet Institute, Brussels, Belgium
FRAGRANCE Part A Safety: Study to Find a Genetic Signature of de Novo Resistance to Letrozole
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2015-01-06
- Lead Sponsor
- Jules Bordet Institute
- Target Recruit Count
- 49
- Registration Number
- NCT00199134
- Locations
- π§πͺ
Jules Bordet Institute, Brussels, Belgium
Efficacy and Activity of BAY 43-9006 in Patients With Recurrent and/or Metastatic Head and Neck Cancer
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2015-05-20
- Lead Sponsor
- Jules Bordet Institute
- Target Recruit Count
- 60
- Registration Number
- NCT00199160
- Locations
- π§πͺ
Jules Bordet Institute, Brussels, Belgium
Topoisomerase II Alpha Gene Amplification and Protein Overexpression Predicting Efficacy of Epirubicin
Phase 2
Terminated
- Conditions
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2008-07-18
- Lead Sponsor
- Jules Bordet Institute
- Target Recruit Count
- 338
- Registration Number
- NCT00162812
- Locations
- π§πͺ
Jules Bordet Institute, Brussels, Belgium
Β© Copyright 2024. All Rights Reserved by MedPath